Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

BIOALLIANCE PHARMA SA (C4X)
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2017 6,10 M
EBIT 2017 -26,1 M
Net income 2017 -20,4 M
Finance 2017 21,3 M
Yield 2017 -
Sales 2018 2,20 M
EBIT 2018 -18,2 M
Net income 2018 -14,9 M
Finance 2018 11,3 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 11,5x
EV / Sales2018 36,3x
Capitalization 91,2 M
More Financials
Company
Onxeo SA is a biotechnology company, which engages in the development of drugs for the treatment of orphan diseases.It produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq and AsiDNA.The company was founded by Gilles Avenard and Dominique Costantini on... 
Sector
Pharmaceuticals
Calendar
03/07Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
2017 ONXEO : Establishes Scientific Advisory Board with International Experts in DNA-..
2017 Onxeo Provides Strategy Update and Reports 2017 Third Quarter Financial Infor..
2017 Onxeo Reports First Instance Decision from the Commercial Court of Paris in t..
2017 Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oli..
2017 ONXEO : Patent Issued for Nanoparticles Loaded with Chemotherapeutic Antitumoral..
2017 ONXEO : announces compelling preclinical data in combination for its two innovat..
2017 Onxeo announces compelling preclinical data in combination for its two innov..
2017 ONXEO : Grants Exclusive Worldwide License of Validive Developed for the Treatme..
2017 ONXEO : Phase 3 hepatocellular carcinoma fail crushes Onxeo
2017 Onxeo Grants Exclusive Worldwide License of Validive® Developed for the Treat..
More news
Sector news : Pharmaceuticals - NEC
01:45p CELGENE : to Buy Juno Therapeutics for $9 Billion -- Update
01:42p Stock futures slightly lower as U.S. shutdown enters third day
01:42p European Corporate Roundup for Monday
01:05p CELGENE : to Buy Juno Therapeutics For $9 Billion
12:10p Global business group 'lit a flame' for long-term U.N. goals - chair
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 2
Average target price 1,55 €
Spread / Average Target -14%
EPS Revisions
Managers
NameTitle
Judith Greciet Chief Executive Officer & Director
Joseph S. Zakrzewski Non-Executive Chairman
Nicolas Fellmann Chief Financial Officer & Secretary
Françoise Bono Chief Scientific Officer
Olivier de Beaumont Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BIOALLIANCE PHARMA SA111
JOHNSON & JOHNSON5.47%395 886
NOVARTIS1.19%227 592
PFIZER1.99%220 189
ROCHE HOLDING LTD.-4.87%211 135
MERCK AND COMPANY8.90%167 132